1887

Abstract

PreS2/S vaccination of chronic hepatitis B virus (HBV) carriers led to a reduction in HBV replication or clearance of virus in 30% of treated patients. This study assessed whether vaccinotherapy of chronic HBV carriers induced the selection of escape mutants in the envelope ‘a’ determinant and whether envelope genetic variability might affect the response to vaccination. No amino acid differences were observed in the ‘a’ determinant between sequences obtained before and after treatment (five responders and seven non-responders). However, alignment with HBV prototype sequences revealed seven amino acid changes. Two mutations (T140S and P127L) diverged from subtype variations. In the complete envelope sequence (five non-responders and five responders), ten amino acid modifications were detected between sequences obtained before and after treatment. The absence of any common mutations did not enable the definition of a hot spot of mutations implicated in the response to vaccination. Moreover, vaccinotherapy does not induce the selection of escape mutants in the ‘a’ determinant.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-82-2-367
2001-02-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/82/2/0820367a.html?itemId=/content/journal/jgv/10.1099/0022-1317-82-2-367&mimeType=html&fmt=ahah

References

  1. Brown S. E., Howard C. R., Zuckerman A. J., Steward M. W. 1984; Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides. Lancet ii:184–187
    [Google Scholar]
  2. Carman W. F., Zanetti A. R., Karayiannis P., Waters J., Manzillo G., Tanzi E., Zuckerman A. J., Thomas H. C. 1990; Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325–329
    [Google Scholar]
  3. Carman W., Thomas H., Domingo E. 1993; Viral genetic variation: hepatitis B virus as a clinical example. Lancet 341:349–353
    [Google Scholar]
  4. Carman W. F., Trautwein C., van Deursen F. J., Colman K., Dornan E., McIntyre G., Waters J., Kliem V., Muller R., Thomas H. C., Manns M. P. 1996; Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 24:489–493
    [Google Scholar]
  5. Chisari F. V., Ferrari C. 1995; Hepatitis B virus immunopathogenesis. Annual Review of Immunology 13:29–60
    [Google Scholar]
  6. Chong-Jin O., Wei Ning C., Shiuan K., Gek Keow L. 1999; Identification of hepatitis B surface antigen variants with alterations outside the ‘a’ determinant in immunized Singapore infants. Journal of Infectious Diseases 179:259–263
    [Google Scholar]
  7. Couillin I., Pol S., Mancini M., Driss F., Brechot C., Tiollais P., Michel M. L. 1999; Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. Journal of Infectious Diseases 180:15–26
    [Google Scholar]
  8. Fontaine H., Thiers V., Pol S. 1999; Hepatitis B virus genotypic resistance to lamivudine. Annals of Internal Medicine 131:716–717
    [Google Scholar]
  9. Gerin J. L., Alexander H., Shih J. W. K., Purcell R. H., Dapolito G., Engle R., Green N., Sutcliffe J. G., Shinnick T. M., Lerner R. A. 1983; Chemically synthesized peptides of hepatitis B surface antigen duplicate the d/y specificities and induce subtype-specific antibodies in chimpanzees. Proceedings of the National Academy of Sciences, USA 80:2365–2369
    [Google Scholar]
  10. Gerken G., Paterlini P., Manns M., Housset C., Terre S., Dienes H. P., Hess G., Gerlich W. H., Berthelot P., Meyer zum Büschenfelde K. H., Brechot C. 1991; Assay of hepatitis B virus DNA by polymerase chain reaction and its relationship to pre-S- and S-encoded viral surface antigens. Hepatology 13:158–166
    [Google Scholar]
  11. Ghany M. G., Ayola B., Villamil F. G., Gish R. G., Rojter S., Vierling J. M., Lok A. S. 1998; Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27:213–222
    [Google Scholar]
  12. Heathcote J., McHutchison J., Lee S., Tong M., Benner K., Minuk G., Wright T., Fikes J., Livingston B., Sette A., Chestnut R. 1999; A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. . Hepatology 30:531–536
    [Google Scholar]
  13. Hsu H. Y., Chang M. H., Liaw S. H., Ni Y. H., Chen H. L. 1999; Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30:1312–1317
    [Google Scholar]
  14. McMahon G., Ehrlich P. H., Moustafa Z. A., McCarthy L. A., Dottavio D., Tolpin M. D., Nadler P. I., Östberg L. 1992; Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 15:757–766
    [Google Scholar]
  15. Magnius L. O., Norder H. 1995; Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 38:24–34
    [Google Scholar]
  16. Niederau C., Heintges T., Lange S., Goldmann G., Niederau C. M., Mohr L., Haussinger D. 1996; Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. New England Journal of Medicine 334:1422–1427
    [Google Scholar]
  17. Norder H., Hammas B., Lee S.-D., Bile K., Couroucé A.-M., Mushahwar I. K., Magnius L. O. 1993; Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. Journal of General Virology 74:1341–1348
    [Google Scholar]
  18. Okamoto H., Omi S., Wang Y., Itoh Y., Tsuda F., Tanaka T., Akahane Y., Miyakawa Y., Mayumi M. 1989; The loss of subtypic determinants in alleles, d/y or w/r, on hepatitis B surface antigen. Molecular Immunology 26:197–205
    [Google Scholar]
  19. Oon C. J., Lim G. K., Ye Z., Goh K. T., Tan K. L., Yo S. L., Hopes E., Harrison T. J., Zuckerman A. J. 1995; Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 13:699–702
    [Google Scholar]
  20. Pol S., Driss F., Michel M. L., Nalpas B., Berthelot P., Brechot C. 1994; Specific vaccine therapy in chronic hepatitis B infection. Lancet 344:342
    [Google Scholar]
  21. Pol S., Michel M. L., Brechot C. 2000; Immune therapy of hepatitis B virus chronic infection. Hepatology 31:548–549
    [Google Scholar]
  22. Protzer-Knolle U., Naumann U., Bartenschlager R., Berg T., Hopf U., Meyer zum Buschenfelde K. H., Neuhaus P., Gerken G. 1998; Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27:254–263
    [Google Scholar]
  23. Wen Y. M., Wu X. H., Hu D. C., Zhang Q. P., Guo S. Q. 1995; Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 345:1575–1576
    [Google Scholar]
  24. Wright T. L., Lau J. Y. 1993; Clinical aspects of hepatitis B virus infection. Lancet 342:1340–1344
    [Google Scholar]
  25. Zoulim F., Trepo C. 1999; New antiviral agents for the therapy of chronic hepatitis B virus infection. Intervirology 42:125–144
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-82-2-367
Loading
/content/journal/jgv/10.1099/0022-1317-82-2-367
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error